Sunitinib Malate Market by Purity (>97%, >98%, >99%), Indication (Gastrointestinal Stromal Tumors (GISTs), Pancreatic Neuroendocrine Tumors, Renal Cell Carcinoma (RCC)) - Global Forecast 2024-2030
수니티닙 말레이트 시장 규모는 2023년에 1억 2,327만 달러로 추정되며, 2024년에는 1억 3,472만 달러에 달하며, CAGR 9.79%로, 2030년까지 2억 3,713만 달러에 달할 것으로 예측됩니다.
세계의 수니티닙 말레이트 시장
FPNV 포지셔닝 매트릭스
FPNV 포지셔닝 매트릭스는 수니티닙 말레이트시장을 평가하는데 있어서 매우 중요합니다. 사업 전략 및 제품 만족도에 관련된 주요 지표를 조사했으며, 벤더의 종합적 평가를 제공합니다. 이 면밀한 분석에 의해 사용자는 각자의 요건에 따른 충분한 정보에 기반한 의사결정을 시행할 수 있습니다. 평가에 기반하여 벤더는 성공의 정도가 다른 4개의 상한으로 분류됩니다. : Forefront(F), Pathfinder(P), Niche(N), Vital(V)
시장 점유율 분석
시장 점유율 분석은 수니티닙 말레이트시장에서 벤더의 현황에 대해 인사이트와 상세 조사를 제공하는 종합적 툴입니다. 전체적인 매출, 고객 기반, 기타 주요 지표에 대해 벤더의 기여도를 면밀하게 비교·분석하는 것으로, 기업의 실적 및 시장 점유율 경쟁시 직면하는 과제에 대해 이해가 깊어질 수 있습니다. 또한 이 분석에 의해 조사 대상 기준년에 관찰된 누적, 단편화의 우위성, 합병의 특징 등의 요인을 포함한 이 분야의 경쟁 특성에 관한 귀중한 인사이트를 얻을 수 있습니다. 이와 같이 상세 정보를 얻는 것으로 벤더는 보다 많은 정보에 기반한 의사결정을 내리고, 시장에서의 경쟁력을 높이기 위한 효과적인 전략을 고안할 수 있습니다.
주요 기업 개요
수니티닙 말레이트시장의 최근 중요한 동향을 심층 파악하고, 주요 벤더와 혁신적인 프로필을 소개하고 있습니다.
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장의 개요
제5장 시장 인사이트
- 시장 역학
- 시장 세분화 분석
- 시장 동향 분석
- 고인플레이션의 누적 영향
- Porter의 Five Forces 분석
- 밸류체인과 중요 경로 분석
- 규제 프레임워크
제6장 수니티닙 말레이트시장 : 순도별
제7장 수니티닙 말레이트시장 : 적응증별
- 위장관기질종양(GIST)
- 췌장내분비종양
- 신세포암(RCC)
제8장 아메리카의 수니티닙 말레이트시장
제9장 아시아태평양의 수니티닙 말레이트시장
- 호주
- 중국
- 인도
- 인도네시아
- 일본
- 말레이시아
- 필리핀
- 싱가포르
- 한국
- 대만
- 태국
- 베트남
제10장 유럽, 중동 및 아프리카 수니티닙 말레이트시장
- 덴마크
- 이집트
- 핀란드
- 프랑스
- 독일
- 이스라엘
- 이탈리아
- 네덜란드
- 나이지리아
- 노르웨이
- 폴란드
- 카타르
- 러시아
- 사우디아라비아
- 남아프리카공화국
- 스페인
- 스웨덴
- 스위스
- 터키
- 아랍에미리트
- 영국
제11장 경쟁 구도
- FPNV 포지셔닝 매트릭스
- 시장 점유율 분석 : 주요 기업별
- 경쟁 시나리오 분석 : 주요 기업별
제12장 경쟁 포트폴리오
- 주요 기업 개요
- Aark Pharmaceuticals
- Active Biotech AB
- Anant Pharmaceuticals Pvt. Ltd.
- AstraZeneca PLC
- Beijing Lunarsun Pharmaceutical Co., Ltd.
- Bio-Techne Corporation
- Brawn Laboratories Ltd.
- Hetero Labs Limited
- Hikma Pharmaceuticals PLC
- JEIL PHARMACEUTICAL CO.,LTD.
- Manus Aktteva Biopharma LLP
- Medichem S.A.
- Medzeel Lifescience
- Nanjing First Pharmaceutical Co. Ltd,
- Natco Pharma Limited
- Pfizer Inc.
- Shilpa Medicare Limited
- Sichuan Xieli Pharmaceutical Co., Ltd.
- Synthland Limited
- Taj Pharma India Limited
- TargetMol Chemicals Inc.
- Teva Pharmaceutical Industries Ltd.
- Vivan Life Science
- 주요 제품 포트폴리오
제13장 부록
KSA
[181 Pages Report] The Sunitinib Malate Market size was estimated at USD 123.27 million in 2023 and expected to reach USD 134.72 million in 2024, at a CAGR 9.79% to reach USD 237.13 million by 2030.
Global Sunitinib Malate Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Sunitinib Malate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sunitinib Malate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Sunitinib Malate Market, highlighting leading vendors and their innovative profiles. These include Aark Pharmaceuticals, Active Biotech AB, Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Beijing Lunarsun Pharmaceutical Co., Ltd., Bio-Techne Corporation, Brawn Laboratories Ltd., Hetero Labs Limited, Hikma Pharmaceuticals PLC, JEIL PHARMACEUTICAL CO.,LTD., Manus Aktteva Biopharma LLP, Medichem S.A., Medzeel Lifescience, Nanjing First Pharmaceutical Co. Ltd,, Natco Pharma Limited, Pfizer Inc., Shilpa Medicare Limited, Sichuan Xieli Pharmaceutical Co., Ltd., Synthland Limited, Taj Pharma India Limited, TargetMol Chemicals Inc., Teva Pharmaceutical Industries Ltd., and Vivan Life Science.
Market Segmentation & Coverage
This research report categorizes the Sunitinib Malate Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Purity
- Indication
- Gastrointestinal Stromal Tumors (GISTs)
- Pancreatic Neuroendocrine Tumors
- Renal Cell Carcinoma (RCC)
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Sunitinib Malate Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sunitinib Malate Market?
- What are the technology trends and regulatory frameworks in the Sunitinib Malate Market?
- What is the market share of the leading vendors in the Sunitinib Malate Market?
- Which modes and strategic moves are suitable for entering the Sunitinib Malate Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Sunitinib Malate Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rise in prevalence of pancreatic neuroendocrine tumors (pNET)
- 5.1.1.2. Availability of limited drug options for treatment of advanced pNET
- 5.1.2. Restraints
- 5.1.2.1. High cost of raw materials for manufacturing of sunitinib malate drug
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research and development by pharmaceutical companies to explore new indications and combinations for sunitinib malate
- 5.1.3.2. Increasing awareness about the benefits of targeted therapies in cancer treatment among patients and healthcare providers
- 5.1.4. Challenges
- 5.1.4.1. Adverse cardiovascular events reported during clinical trials
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Sunitinib Malate Market, by Purity
- 6.1. Introduction
- 6.2. >97%
- 6.3. >98%
- 6.4. >99%
7. Sunitinib Malate Market, by Indication
- 7.1. Introduction
- 7.2. Gastrointestinal Stromal Tumors (GISTs)
- 7.3. Pancreatic Neuroendocrine Tumors
- 7.4. Renal Cell Carcinoma (RCC)
8. Americas Sunitinib Malate Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Sunitinib Malate Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Sunitinib Malate Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Aark Pharmaceuticals
- 12.1.2. Active Biotech AB
- 12.1.3. Anant Pharmaceuticals Pvt. Ltd.
- 12.1.4. AstraZeneca PLC
- 12.1.5. Beijing Lunarsun Pharmaceutical Co., Ltd.
- 12.1.6. Bio-Techne Corporation
- 12.1.7. Brawn Laboratories Ltd.
- 12.1.8. Hetero Labs Limited
- 12.1.9. Hikma Pharmaceuticals PLC
- 12.1.10. JEIL PHARMACEUTICAL CO.,LTD.
- 12.1.11. Manus Aktteva Biopharma LLP
- 12.1.12. Medichem S.A.
- 12.1.13. Medzeel Lifescience
- 12.1.14. Nanjing First Pharmaceutical Co. Ltd,
- 12.1.15. Natco Pharma Limited
- 12.1.16. Pfizer Inc.
- 12.1.17. Shilpa Medicare Limited
- 12.1.18. Sichuan Xieli Pharmaceutical Co., Ltd.
- 12.1.19. Synthland Limited
- 12.1.20. Taj Pharma India Limited
- 12.1.21. TargetMol Chemicals Inc.
- 12.1.22. Teva Pharmaceutical Industries Ltd.
- 12.1.23. Vivan Life Science
- 12.2. Key Product Portfolio
13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
